Unknown

Dataset Information

Immunological inflammatory biomarkers as prognostic predictors for advanced hepatocellular carcinoma.


ABSTRACT:

Background

The immunological inflammatory biomarkers for advanced hepatocellular carcinoma are unclear. We aimed to investigate the association of immunity and inflammatory status with treatment outcomes in patients with advanced hepatocellular carcinoma who received molecular-targeted agents as primary treatment.

Patients and methods

We enrolled 728 consecutive patients with advanced hepatocellular carcinoma who received sorafenib (n = 554) or lenvatinib (n = 174) as primary treatment in Japan between May 2009 and June 2020. Changes in the neutrophil-to-lymphocyte ratio before and 1 month after treatment and their impact on survival were evaluated. The cut-off values of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for predicting overall and progression-fr

SUBMITTER: Nakano M 

PROVIDER: S-EPMC7807940 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature